BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Su Y, Qin H, Chen C, Wang S, Zhang S, Zhang D, Jin M, Peng Y, He L, Wang X, Qian S, Qin M, Ge M, Zhang F, Zeng Q, Wang H, Ma X, Ni X. Treatment and outcomes of 1041 pediatric patients with neuroblastoma who received multidisciplinary care in China. Pediatr Investig 2020;4:157-67. [PMID: 33150309 DOI: 10.1002/ped4.12214] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
Number Citing Articles
1 Liang Y, Wang Q, Zhang X, Zhang M, Du B, Cheng W, Wang H, Li L, Hou G, Zhang W. Dual isothermal amplification all-in-one approach for rapid and highly sensitive quantification of plasma circulating MYCN gene of neuroblastoma. Anal Biochem 2022;:114922. [PMID: 36162447 DOI: 10.1016/j.ab.2022.114922] [Reference Citation Analysis]
2 Liu Q, Wang S, Chu P, Sun J, Jin Y, Guo Y, Ma X, He L, Su Y, Zhang J, Peng Y, Li Y, Zhang X, Sun N, Liu Z, Ni X. Clinical and Surgical Outcome Differences on the Basis of Pathology Category in Cervical Neuroblastic Tumors. Journal of Pediatric Surgery 2022. [DOI: 10.1016/j.jpedsurg.2022.07.008] [Reference Citation Analysis]
3 Lu XY, Qu LJ, Duan XL, Zuo W, Sai K, Rui G, Gong XF, Ding YB, Gao Q. Impact of 11q Loss of Heterozygosity Status on the Response of High-Risk Neuroblastoma With MYCN Amplification to Neoadjuvant Chemotherapy. Front Pediatr 2022;10:898918. [PMID: 35757140 DOI: 10.3389/fped.2022.898918] [Reference Citation Analysis]
4 Fan H, Xing T, Hong H, Duan C, Zhao W, Zhao Q, Wang X, Huang C, Zhu S, Jin M, Su Y, Gao C, Ma X. The expression of PHOX2B in bone marrow and peripheral blood predicts adverse clinical outcome in non-high-risk neuroblastoma. Pediatr Hematol Oncol 2021;:1-14. [PMID: 34752187 DOI: 10.1080/08880018.2021.1995090] [Reference Citation Analysis]